Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test cutoff could spot hidden cause of high blood pressure

NCT ID NCT07621458

Knowledge-focused Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a new cutoff for a blood test (aldosterone-renin ratio) can better identify people with primary aldosteronism, a common cause of high blood pressure. About 150 adults with hypertension and certain lab results will be tested using the new cutoff and then followed after treatment. The goal is to see how many tests are needed to find one case and to find the best cutoff for Korean patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with hypertension who have an aldosterone-to-renin ratio (ARR) \>20 and meet criteria for intermediate probability of lateralizing primary aldosteronism.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of hypertension or current use of antihypertensive medications * Plasma renin activity (PRA) ≤1 ng/mL/hr * Plasma aldosterone concentration (PAC) ≥10 ng/dL by immunoassay or ≥7.5 ng/dL by liquid chromatography-tandem mass spectrometry (LC-MS/MS) * Aldosterone-to-renin ratio (ARR) \>20 by immunoassay or \>15 by LC-MS/MS * Participants meeting criteria for intermediate probability of lateralizing primary aldosteronism * For participants with ARR values between 20 and 30, repeat ARR measurement within 26 weeks demonstrating persistent ARR \>20 Exclusion Criteria: * Current use of mineralocorticoid receptor antagonists or amiloride that cannot be discontinued according to study protocol * Previous adrenalectomy * Chronic kidney disease stage 4 or higher (estimated glomerular filtration rate \<30 mL/min/1.73 m²) * Pregnancy * Current use of combined estrogen- and progesterone-containing oral contraceptive pills or hormone replacement therapy * High probability primary aldosteronism defined as hypokalemia with PRA \<0.2 ng/mL/hr and PAC \>20 ng/dL by immunoassay or \>15 ng/dL by LC-MS/MS * Low probability primary aldosteronism defined as PAC \<11 ng/dL by immunoassay or \<8 ng/dL by LC-MS/MS * Inability to undergo saline infusion test according to investigator judgment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary aldosteronism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary aldosteronism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Seoul National University Hospital

    RECRUITING

    Seoul, Korea, Republic of, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.